Drug Trial Radar · NCT01256671
DHEA Against Vaginal Atrophy - Safety Study of 12 Months
Last checked: Nov 20, 2026Latest source record: Oct 18, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
530
Actual
Start
Dec 2010
Primary completion
Jul 2012
Study completion Dec 2012
Sponsor
- Lead sponsor
- EndoCeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 8, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 40 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase III trial is to assess the long-term safety of intravaginal dehydroepiandrosterone (DHEA) in non-hysterectomized postmenopausal women with vaginal atrophy aged 40 to 75 years.
Conditions
- Vaginal Atrophy
Interventions
DHEADrug
Vaginal suppository containing 0.5% (6.5 mg) DHEA; daily dosing with one suppository for 52 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Long-term Safety of Intravaginal Prasterone (DHEA): EndometriumTime frame: Baseline and Week 52 (or discontinuation)
- Long-term Safety of Intravaginal Prasterone (DHEA): Serum Steroid LevelsTime frame: Baseline and Week 52
Locations
41 sites in 2 countries. Site status is shown where the registry gives one.
EndoCeutics site # 39
Montgomery, Alabama
EndoCeutics site # 14
Tucson, Arizona
EndoCeutics site # 21
Sacramento, California
EndoCeutics site # 30
San Diego, California
EndoCeutics site # 17
San Diego, California
EndoCeutics site # 36
Denver, Colorado
EndoCeutics site # 42
Milford, Connecticut
EndoCeutics site # 07
Washington D.C., District of Columbia
EndoCeutics site # 45
Boynton Beach, Florida
EndoCeutics site # 26
Jacksonville, Florida
EndoCeutics site # 41
West Palm Beach, Florida
EndoCeutics site # 23
Sandy Springs, Georgia
EndoCeutics site # 10
Meridian, Idaho
EndoCeutics site # 27
Baltimore, Maryland
EndoCeutics site # 22
Kalamazoo, Michigan
EndoCeutics site # 25
Lincoln, Nebraska
EndoCeutics site # 24
Omaha, Nebraska
EndoCeutics site # 28
Moorestown, New Jersey
EndoCeutics site # 50
Neptune City, New Jersey
EndoCeutics site # 44
New Brunswick, New Jersey
EndoCeutics site # 19
New York, New York
EndoCeutics site # 16
Durham, North Carolina
EndoCeutics site # 33
Beachwood, Ohio
EndoCeutics site # 05
Cleveland, Ohio
EndoCeutics site # 47
Cleveland, Ohio
EndoCeutics site # 15
Columbus, Ohio
EndoCeutics site # 35
Pittsburgh, Pennsylvania
EndoCeutics site # 09
West Jordan, Utah
EndoCeutics site # 31
Charlottesville, Virginia
EndoCeutics site # 03
Norfolk, Virginia
EndoCeutics site # 38
Renton, Washington
EndoCeutics site # 13
Calgary, Alberta, Canada
EndoCeutics site # 06
Bathurst, New Brunswick, Canada
EndoCeutics site # 04
Drummondville, Quebec, Canada
EndoCeutics site # 34
Montreal, Quebec, Canada
EndoCeutics site # 12
Montreal, Quebec, Canada
EndoCeutics site # 02
Québec, Quebec, Canada
EndoCeutics site # 01
Québec, Quebec, Canada
EndoCeutics site # 18
Saint Romuald, Quebec, Canada
EndoCeutics site # 08
Shawinigan, Quebec, Canada
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.